The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

@article{VanAllen2014TheGL,
  title={The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.},
  author={Eliezer M. Van Allen and Nikhil Wagle and Antje Sucker and Daniel J. Treacy and Cory M. Johannessen and Eva M. Goetz and Chelsea S. Place and Amaro Taylor-Weiner and Steven R. Whittaker and Gregory V. Kryukov and Eran Hodis and Mara Rosenberg and Aaron McKenna and Kristian Cibulskis and Deborah N. Farlow and Lisa Zimmer and Uwe Hillen and Ralf Gutzmer and Simone M Goldinger and Selma Ugurel and Helen J Gogas and F Egberts and Carola Berking and Uwe Trefzer and Carmen Loquai and Benjamin Weide and Jessica C. Hassel and S. Gabriel and Scott L. Carter and Gad Getz and Levi A. Garraway and Dirk Schadendorf},
  journal={Cancer discovery},
  year={2014},
  volume={4 1},
  pages={
          94-109
        }
}
Most patients with BRAF(V600)-mutant metastatic melanoma develop resistance to selective RAF kinase inhibitors. The spectrum of clinical genetic resistance mechanisms to RAF inhibitors and options for salvage therapy are incompletely understood. We performed whole-exome sequencing on formalin-fixed, paraffin-embedded tumors from 45 patients with BRAF(V600)-mutant metastatic melanoma who received vemurafenib or dabrafenib monotherapy. Genetic alterations in known or putative RAF inhibitor… 

Figures and Tables from this paper

PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma.
TLDR
These results provide a rationale for cotargeting BRAF and the PI3K/AKT pathway in patients with BRAF-mutant melanoma when tumors have concurrent loss-of-function mutations in PTEN, a metric that combines tumor regression and duration of treatment response.
Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
TLDR
This systematic review examines all of the potential ways that melanoma cells develop resistance to BRAF inhibitors and investigates the literature on acquired v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor resistance in patients with melanoma.
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
TLDR
Analysis of BRAF(V600)-mutant melanoma metastases derived from 10 patients treated with the combination of dabrafenib and trametinib for resistance mechanisms and genetic correlates of response finds the functional differences between these kinases and the preponderance of MEK2 mutations in combination therapy-resistant melanomas.
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.
TLDR
A comprehensive effort to define mechanisms underlying drug resistance with the goal of guiding development of therapeutic strategies to overcome this limitation is undertaken, and therapeutic combinations capable of overcoming drug resistance are identified.
Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity
TLDR
There was no similar pattern of phenotypic alterations among eleven resistant cell lines, including expression/activity of crucial regulators, such as MITF, AXL, SOX, and NGFR, which suggests that patient-to-patient variability is richer and more nuanced than previously described.
Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma
TLDR
A key implication of the study is that the combination of CDK4/6 and MEK inhibitors overcomes acquired resistance to BRAF/MEK inhibitors, and loss of CDKN2A may represent a biomarker of response to the combination.
The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies
TLDR
The new sequencing, molecular, and bioinformatic technologies exploiting the melanoma genome for treatment decisions have significantly improved the understanding of melanoma pathogenesis, treatment response, and resistance for either targeted treatment or immune checkpoint blockade.
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
...
...

References

SHOWING 1-10 OF 63 REFERENCES
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
TLDR
Dabrafenib and trametinib were safely combined at full monotherapy doses, and the rate of pyrexia was increased with combination therapy, whereas the rates of proliferative skin lesions was nonsignificantly reduced.
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.
TLDR
NF1 mutations were observed in BRAF-mutant tumor cells that are intrinsically resistant to RAF inhibition and in melanoma tumors obtained from patients exhibiting resistance to vemurafenib, thus showing the clinical potential for NF1-driven resistance to RAF/MEK-targeted therapies.
Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
TLDR
The results suggest that genetic markers associated with response and PFS in patients treated with dabrafenib should be considered in the design and interpretation of future trials with selective BRAF inhibitors in advanced melanoma patients.
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
TLDR
It is shown that melanomas escape B-RAF(V600E) targeting not through secondary B-RF(V 600E) mutations but via receptor tyrosine kinase (RTK)-mediated activation of alternative survival pathway(s) or activated RAS-mediated reactivation of the MAPK pathway, suggesting additional therapeutic strategies.
Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression
TLDR
The coexistence within the same patient of different molecular mechanisms of resistance to vemurafenib affecting different metastatic sites is described, which has direct implications for the clinical management of BRAF-mutant melanoma.
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
TLDR
Vemurafenib induces clinical responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma, and the median overall survival in this study with a long follow-up was approximately 16 months.
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.
TLDR
It is shown that the presence of a downstream mutation in MEK1 does not necessarily make BRAF–mutant melanomas resistant to BRAF inhibitors, and activating MeK1 exon 3 mutations identified herein and concurrent with V600E/KBRAF do not cause BRAFi resistance in melanoma.
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
TLDR
SCH772984 is a novel and selective inhibitor of ERK1/2 that displays behaviors of both type I and type II kinase inhibitors and effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor-resistant models as well as in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors.
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF
TLDR
Genetic alterations that co-occur with oncogenic BRAF in melanoma and abrogate cellular dependence upon this oncogene provide a genetic basis for the heterogeneity of clinical outcomes in patients treated with targeted inhibitors of the mitogen-activated protein kinase pathway.
...
...